UY38550A - NLRP3 FLAMASOMA INHIBITING COMPOUNDS, COMPOSITIONS, COMBINATIONS AND RELATED METHODS - Google Patents

NLRP3 FLAMASOMA INHIBITING COMPOUNDS, COMPOSITIONS, COMBINATIONS AND RELATED METHODS

Info

Publication number
UY38550A
UY38550A UY0001038550A UY38550A UY38550A UY 38550 A UY38550 A UY 38550A UY 0001038550 A UY0001038550 A UY 0001038550A UY 38550 A UY38550 A UY 38550A UY 38550 A UY38550 A UY 38550A
Authority
UY
Uruguay
Prior art keywords
nlrp3
compositions
flamasoma
combinations
related methods
Prior art date
Application number
UY0001038550A
Other languages
Spanish (es)
Inventor
Christopher Farady
Nina Gommermann
Philipp Janser
Angela Mackay
Henri Mattes
Nikolaus Johannes Stiefl
Juraj Velcicky
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2019/056278 external-priority patent/WO2020021447A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY38550A publication Critical patent/UY38550A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de tienopirrolotriazinacetamida de la fórmula (I): en donde R1, R2 y R3 se definen en el presente documento, que inhiben la actividad inflamatoria de la proteína 3 receptora de tipo NOD (NLRP3). La invención se refiere, además, a los procesos para su preparación, composiciones farmacéuticas y medicamentos que los contienen, y su uso en el tratamiento de enfermedades y trastornos mediados por NLRP3.The present invention relates to new thienopyrrolotriazineacetamide compounds of formula (I): wherein R1, R2 and R3 are defined herein, which inhibit the inflammatory activity of NOD-like receptor protein 3 (NLRP3). The invention further relates to the processes for their preparation, pharmaceutical compositions and drugs containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

UY0001038550A 2019-05-17 2020-01-22 NLRP3 FLAMASOMA INHIBITING COMPOUNDS, COMPOSITIONS, COMBINATIONS AND RELATED METHODS UY38550A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19175246 2019-05-17
PCT/IB2019/056278 WO2020021447A1 (en) 2018-07-25 2019-07-23 Nlrp3 inflammasome inhibitors

Publications (1)

Publication Number Publication Date
UY38550A true UY38550A (en) 2020-12-31

Family

ID=66685350

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038550A UY38550A (en) 2019-05-17 2020-01-22 NLRP3 FLAMASOMA INHIBITING COMPOUNDS, COMPOSITIONS, COMBINATIONS AND RELATED METHODS

Country Status (4)

Country Link
AR (1) AR117863A1 (en)
EA (1) EA202190329A1 (en)
TW (1) TW202110856A (en)
UY (1) UY38550A (en)

Also Published As

Publication number Publication date
EA202190329A1 (en) 2021-05-18
AR117863A1 (en) 2021-09-01
TW202110856A (en) 2021-03-16

Similar Documents

Publication Publication Date Title
DOP2021000019A (en) INFLAMASOME INHIBITORS NLRP3
CL2021003012A1 (en) nlrp3 inflammasome inhibitors
ECSP24014832A (en) NLRP3 INHIBITORS
DOP2021000183A (en) CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTI-CANCER AGENTS
CO2019011762A2 (en) Compounds that inhibit mcl-1 protein
EA202091512A1 (en) SULFONYLUREA DERIVATIVES AS NLRP3 INFLAMMASOM MODULATORS
CO2018000344A2 (en) 1,4-substituted piperidine derivatives
BR112016028642A2 (en) compound, pharmaceutical composition, method of treating a disease or condition, method of inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide, method of inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, and, use of a compound, salt, isomer or a pharmaceutically acceptable mixture thereof.
CL2013002690A1 (en) Compounds derived from bis (fluoroalkyl) -1,4-benzodiazepinone, notch inhibitors; crystalline compound; pharmaceutical composition that includes them; pharmaceutical combination; and its use for the treatment of cancer.
CL2022000201A1 (en) akr1c3-dependent tricyclic inhibitors of kars
BR112016028818A2 (en) pharmaceutical composition, methods of treating a disease or condition, inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide and inhibiting excessive or destructive immune reactions or cancer cell growth or proliferation, kit, compound, salt, isomer, or a pharmaceutically acceptable mixture thereof, and, use of a compound, a salt, isomer, or a pharmaceutically acceptable mixture thereof.
ECSP13013024A (en) 1,3-OXAZINES AS INHIBITORS OF BACE1 AND / OR BACE2
ECSP13013068A (en) HALOGENOALQUIL-1,3-OXAZINAS AS INHIBITORS OF THE BACE1 AND / OR BACE2
UY31885A (en) DERIVED FROM THE 1, 3, 5-TRIAZINA-2, 4-DIAMINAS-6-SUBSTITUTED-N-SUBSTITUTED AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, COMPOSITIONS AND APPLICATIONS.
EA201990388A1 (en) CXCR7 PIPERIDINE MODULATORS
BR112016028814A2 (en) pharmaceutical composition, methods of treating a disease or condition, inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, compound, a salt, an isomer, or a pharmaceutically acceptable mixture thereof, and, use of a compound, a salt, an isomer, or a pharmaceutically acceptable mixture thereof?
UY38625A (en) COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
UY33655A (en) CCR30 CO-CRYSTALS AND SALES OF INHIBITORS
MX2020011405A (en) Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (rorï’) and pharmaceutical uses thereof.
BR112021011325A2 (en) Rapamycin derivatives
CR20170513A (en) USEFUL PIRAZOL DERIVATIVES AS INHIBITORS OF 5-LI-POXIGENASA ACTIVATING PROTEIN (FLAP).
UY37729A (en) NEW COMPOUNDS THAT INHIBIT THE ACTIVITY OF Nav1.7
CR20180368A (en) RENTING DIHYDROQUINOLINSULFONAMIDE COMPOUNDS
CO2022012884A2 (en) Fused Amino Pyrimidine Compounds
AR117844A1 (en) THIAZOLOPYRIDINE DERIVATIVES AS ANTAGONISTS OF THE ADENOSINE RECEPTOR